NYX-2925: Phase I started

Aptinyx began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single doses of 50-1,200 mg oral NYX-2925 and once-daily doses of 150-600 mg NYX-2925 for 7 days in about 70 healthy vo...